All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Johnson & Johnson's Rybrevant (amivantamab) wins Scotland approval for EGFR exon 20 non-small cell lung cancer
Antibody, cancer, monoclonal antibody, non-small cell lung cancer, EGFR target, combination therapy - Read more

THE GOOD
Business Development & Partnerships

Dr. Reddy's, Immutep partner on phase 3 immunotherapy eftilagimod alpha, $20M upfront + $349.5M biobucks
Licensing deal, oncology, immunotherapy, milestone payments - Read more

PRESENTED BY PROMOVEO HEALTH
Contract Sales Reps = Fast Deployment + Lower Cost

We've built 100+ pharma sales teams for companies of all sizes, and we can help you.

We build agile field teams that scale based on your needs - all with fast deployment + lower cost than full-time reps.

See how flexible can work - click here to learn more.

✅ More Good News ✅

THE GOOD
Clinical Trials

Protagonist Therapeutics, Takeda report positive 52-week Ph3 data for rusfertide in polycythemia vera treatment
Small molecule, hematological disorder, polycythemia vera, hematocrit control, phlebotomy reduction - Read more

Amphista Therapeutics' AMX-883 BRD9 degrader shows preclinical promise in acute myeloid leukemia, targeting 2026 Ph1 start
Small molecule, cancer, protein degrader, acute myeloid leukemia, BRD9 target, combination therapy - Read more

Ascletis reports 7.7% weight loss for ASC30 (oral GLP-1 agonist) in Ph2 obesity study
Small molecule, metabolic, GLP-1 agonist, obesity, oral formulation - Read more

UCB's Fintepla achieves Ph3 success in CDKL5 deficiency disorder, plans regulatory filing for third epilepsy indication
Small molecule, neurological, epilepsy, CDKL5 deficiency disorder, seizure reduction - Read more

Biogen, Stoke Therapeutics' zorevunersen shows 82% seizure reduction in Dravet syndrome patients through 24 months
Antisense oligonucleotide, neurological, epilepsy, Dravet syndrome, SCN1A gene, seizure reduction - Read more

Dyne Therapeutics' zeleciment rostudirsen (z-rostudirsen) shows strong Ph1/2 results in Duchenne muscular dystrophy, targeting BLA filing
Antisense oligonucleotide, neurological, exon skipping therapy, Duchenne muscular dystrophy, dystrophin restoration - Read more

Johnson & Johnson's CARVYKTI (ciltacabtagene autoleucel) shows durable remissions in Ph3 trial for relapsed multiple myeloma
Cell therapy, cancer, CAR-T, multiple myeloma, BCMA target, second-line therapy - Read more

Terns Pharmaceuticals' TERN-701 shows 74% major molecular response rate in Ph1 chronic myeloid leukemia trial
Small molecule, cancer, kinase inhibitor, chronic myeloid leukemia, BCR-ABL target - Read more

Wave Life Sciences reports positive Ph1 results for WVE-007 RNA treatment targeting obesity showing fat reduction
RNA interference, metabolic, RNAi, obesity, INHBE target - Read more

Recursion's REC-4881 shows positive Ph2 results reducing polyp burden in familial adenomatous polyposis patients
Small molecule, cancer, MEK inhibitor, familial adenomatous polyposis, APC target - Read more

Kymera's KT-621 STAT6 degrader shows promising Ph1b results in atopic dermatitis, matching Dupixent efficacy
Small molecule, autoimmune, protein degrader, atopic dermatitis, STAT6 target - Read more

AstraZeneca's AZD0120 dual CAR-T achieves 100% response rate in Ph1b relapsed refractory multiple myeloma trial
Cell therapy, cancer, CAR-T, multiple myeloma, BCMA target, CD19 target - Read more

Orca Bio presents positive Ph1 data for Orca-Q without graft versus host disease prophylaxis in blood cancers
Cell therapy, cancer, CAR-T, acute lymphoblastic leukemia, allogeneic transplant, GvHD - Read more

UCB's fenfluramine meets Ph3 endpoints, significantly reducing seizures in CDKL5 Deficiency Disorder patients
Small molecule, neurological, epilepsy, CDKL5 deficiency disorder, fenfluramine, seizure reduction - Read more

Exicure reports positive Ph2 data for burixafor targeting CXCR4 in multiple myeloma stem cell mobilization
Small molecule, cancer, CXCR4 inhibitor, multiple myeloma, stem cell mobilization, autologous transplant - Read more

Kallyope reports positive Ph2b results for elismetrep (TRPM8 antagonist) in acute migraine treatment
Small molecule, neurological, TRPM8 antagonist, migraine, oral therapy - Read more

Cogent Biosciences reports positive Ph3 results for bezuclastinib targeting KIT in advanced systemic mastocytosis
Small molecule, cancer, kinase inhibitor, systemic mastocytosis, KIT inhibitor - Read more

Structure Therapeutics reports positive Ph2 results for aleniglipron targeting GLP-1 receptor in obesity treatment
Small molecule, metabolic, GLP-1 receptor agonist, obesity, aleniglipron - Read more

BioNTech's gotistobart shows improved Ph3 survival for non-small cell lung cancer despite tolerability concerns
Antibody, cancer, monoclonal antibody, non-small cell lung cancer, CTLA-4 target, immune-related adverse events - Read more

Kura Oncology's Komzifti shows 73% complete response rate in Ph1 trial for newly-diagnosed acute myeloid leukemia
Small molecule, cancer, menin inhibitor, acute myeloid leukemia, combination therapy - Read more [Paywall]

THE GOOD
Fundraises

Pan Cancer T raises €10M ($11.64M) funding for TCR-T cell therapy trial
Cell therapy, oncology, TCR-T, clinical-stage - Read more

Convergen raises $10M Seed, developing targeted protein degradation therapies for neurodegenerative disorders
Protein degradation, neurological, platform technology, preclinical - Read more

THE GOOD
Mergers & Acquisitions

Mirum Pharmaceuticals acquires Bluejay Therapeutics for $620M to gain hepatitis D drug brelovitug nearing Phase 3 results
Monoclonal antibody, infectious disease, strategic, major transaction - Read more

Sandoz completes acquisition of Just-Evotec Biologics, gains continuous-manufacturing technology to strengthen biosimilars leadership
Biosimilars, strategic, major transaction, operational - Read more

THE GOOD
Politics & Policy

Singapore allocates $28.5 billion over five years for deep tech research including AI and biotechnology development
Government funding, biotechnology, artificial intelligence, strategic, major investment - Read more

THE GOOD
Regulatory

China launches first private insurance formulary featuring drugs from Pfizer, Lilly, J&J, others
Cell therapy, oncology, strategic, market access - Read more

PRESENTED BY YOU?
Get the attention of 2300+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Approvals & Labels

FDA delays decision on Agios' Pyrukynd (mitapivat) pyruvate kinase activator label expansion for alpha- and beta-thalassemia
Small molecule, blood disorders, pyruvate kinase activator, thalassemia, hemolytic anemia - Read more

THE BAD
Business Development & Partnerships

AbbVie, Ose Immunotherapeutics revise inflammation drug partnership with Ose retaking phase 1 development responsibilities
Licensing deal, chronic inflammation, antibody, milestone payments - Read more

GSK, Ideaya Biosciences end five-year cancer collaboration, terminating Pol Theta and Werner Helicase programs
Partnership termination, oncology, small molecule, synthetic lethality - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here